GSK Plc: FDA Grants Approval For Jemperli For Patients With DMMR Recurrent Endometrial Cancer
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
(RTTNews) – GSK plc (GSK.L, GSK) announced the US FDA granted full approval for Jemperli (dostarlimab-gxly) for the treatment of adult patients with mismatch repair-deficient recurrent or advanced endometrial cancer, as determined by a US FDA-approved test, that has progressed on
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-2155522534-8510213a5205498c9cf10239a6d1542b.jpg "The 10 Best Alternatives to Craigslist")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1480323436-0009268132e143869758c3f6d2a4642b.jpg "<div>4 Basic Pointers When Investing Other People's Money</div>")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1132711574-388eca9691b24bcea4b6ddac521bac25.jpg "Divorce Planning Checklist")
:max_bytes(150000):strip_icc():format(jpeg)/PaperworkatDesk-1a3837aec527439dbbf86d99a89611ba.jpg "2024 and 2025 Federal Income Tax Brackets, Standard Deductions, and Tax Rates")